Hassaniazad, 40 patient curcumin late treatment RCT: 46% worse recovery [p=0.9] https://c19p.org/hassaniazad
copied to clipboard
A triple-blind, placebo-controlled, randomized clinical trial to evaluate the effect of curcumin-containing nanomicelles on cellular immune responses subtypes and clinical outcome in COVID-19 patients
et al., Phytotherapy Research, doi:10.1002/ptr.7294
Small RCT with 40 low risk patients in Iran, 20 treated with nano-curcumin, showing no significant difference in outcomes with treatment. Authors note that treatment can improve peripheral blood inflammatory indices and modulate immune response by decreasing Th1 and Th17 responses, increasing T regulatory responses, further reducing IL-17 and IFN-γ, and increasing suppressive cytokines TGF-β and IL-4.
|
relative improvement in SpO2, 45.7% worse, RR 1.46, p = 0.90, treatment 20, control 20.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Hassaniazad et al., 9/19/2021, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, Middle East, peer-reviewed, 12 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.